The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: Relationship to clinical effects in mood disorders

Neuropsychopharmacology

Volumn 32, Issue 4, 2007, Pages 793-802

  Du, Jing ^a   Suzuki, Katsuji ^a   Wei, Yanling ^a   Wang, Yun ^a   Blumenthal, Rayah ^a   Chen, Zheng ^a   Falke, Cynthia ^a   Zarate Jr , Carlos A ^a   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

AMPA receptors; Imipramine; Lamotrigine; Phosphorylation; Riluzole; Valproate

Indexed keywords

AMPA RECEPTOR; ANTICONVULSIVE AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUTAMATE RECEPTOR 1; GLUTAMATE RECEPTOR 2; IMIPRAMINE; LAMOTRIGINE; RILUZOLE; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE DEPOLARIZATION; MEMBRANE POTENTIAL; MOOD DISORDER; NERVE CELL; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTICONVULSANTS; BIOTINYLATION; BLOTTING, WESTERN; CELL MEMBRANE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EMBRYO; HIPPOCAMPUS; NEURONS; PHOSPHORYLATION; PROTEIN TRANSPORT; RATS; RECEPTORS, AMPA; TIME FACTORS;

EID: 33947213976     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301178     Document Type: Article

References (52)

1. Ahmad S, Fowler LJ, Whitton PS (2004). Effects of acute and chronic lamotrigine treatment on basal and stimulated extracellular amino acids in the hippocampus of freely moving rats. Brain Res 1029: 41-47.
2. Alt A, Witkin JM, Bleakman D (2005). AMPA receptor potentiators as novel antidepressants. Curr Pharm Des 11: 1511-1527.
3. Banke TG, Bowie D, Lee H, Huganir RL, Schousboe A, Traynelis SF (2000). Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. J Neurosci 20: 89-102.
4. 2+/calmodulin-dependent protein kinase II regulatory phosphorylation site in the alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate-type glutamate receptor. J Biol Chem 272: 32727-32730.
5. Bazil CW (2002). New antiepileptic drugs. Neurologist 8: 71-81.
6. Bensimon G, Lacomblez L, Meininger V (1994). A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330: 585-591.
7. Black MD (2005). Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berlin) 179: 154-163.
8. Boireau A, Dubedat P, Bordier F, Imperato A, Moussaoui S (2000). The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. Neuropharmacology 39: 1016-1020.
9. Bonanno G, Giambelli R, Raiteri L, Tiraboschi E, Zappettini S, Musazzi L et al (2005). Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 25: 3270-3279.
10. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 60: 79-88.
11. Carlezon Jr WA, Nestler EJ (2002). Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse? Trends Neurosci 25: 610-615.
12. Choi KH, Clements RL, Greenshaw AJ (2005). Simultaneous AMPA/kainate receptor blockade and dopamine D(2/3) receptor stimulation in the nucleus accumbens decreases brain stimulation reward in rats. Behav Brain Res 158: 79-88.
13. Coyle JT, Duman RS (2003). Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38: 157-160.
14. 2+/calmodulin- kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionate type glutamate receptors. Proc Natl Acad Sci USA 96: 3269-3274.
15. Donati RJ, Rasenick MM (2003). G protein signaling and the molecular basis of antidepressant action. Life Sci 73: 1-17.
16. Du J, Feng L, Yang F, Lu B (2000). Activity- and Ca(2+)-dependent modulation of surface expression of brain-derived neurotrophic factor receptors in hippocampal neurons. J Cell Biol 150: 1423-1434.
17. Du J, Gray NA, Falke C, Yuan P, Szabo S, Manji HK (2003). Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression. Ann NY Acad Sci 1003: 378-380.
18. Du J, Gray NA, Falke CA, Chen W, Yuan P, Szabo ST et al (2004). Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci 24: 6578-6589.
19. Ernst CL, Goldberg JF (2003). Antidepressant properties of anticonvulsant drugs for bipolar disorder. J Clin Psychopharmacol 23: 182-192.
20. Esteban JA, Shi SH, Wilson C, Nuriya M, Huganir RL, Malinow R (2003). PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity. Nat Neurosci 6: 136-143.
21. Evins AE (2003). Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry 64(Suppl 8): 9-14.
22. Gray NA, Du J, Falke CS, Yuan P, Manji HK (2003). Lithium regulates total and synaptic expression of the AMPA glutamate receptor GluR2 in vitro and in vivo. Ann NY Acad Sci 1003: 402-404.
23. Groeneveld GJ, Van Kan HJ, Kalmijn S, Veldink JH, Guchelaar HJ, Wokke JH et al (2003). Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms. Neurology 61: 1141-1143.
24. Hayashi Y, Shi SH, Esteban JA, Piccini A, Poncer JC, Malinow R (2000). Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. Science 287: 2262-2267.
25. Hirsch LJ, Weintraub D, Du Y, Buchsbaum R, Spencer HT, Hager M et al (2004). Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 63: 1022-1026.
26. Kaddis FG, Uretsky NJ, Wallace LJ (1995). DNQX in the nucleus accumbens inhibits cocaine-induced conditioned place preference. Brain Res 697: 76-82.
27. Kendell SF, Krystal JH, Sanacora G (2005). GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets 9: 153-168.
28. Knapp RJ, Goldenberg R, Shuck C, Cecil A, Watkins J, Miller C et al (2002). Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol 440: 27-35.
29. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G et al (2002). Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 7(Suppl 1): S71-S80.
30. Kwan P, Brodie MJ (2001). Effectiveness of first antiepileptic drug. Epilepsia 42: 1255-1260.
31. Lee HK, Barbarosie M, Kameyama K, Bear MF, Huganir RL (2000). Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature 405: 955-959.
32. Lee HK, Kameyama K, Huganir RL, Bear MF (1998). NMDA induces long-term synaptic depression and dephosphorylation of the GluR1 subunit of AMPA receptors in hippocampus. Neuron 21: 1151-1162.
33. Lees G, Leach MJ (1993). Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res 612: 190-199.
34. Li X, Tizzano JP, Griffey K, Clay M, Lindstrom T, Skolnick P (2001). Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 40: 1028-1033.
35. Li Y, Vartanian AJ, White FJ, Xue CJ, Wolf ME (1997). Effects of the AMPA receptor antagonist NBQX on the development and expression of behavioral sensitization to cocaine and amphetamine. Psychopharmacology (Berlin) 134: 266-276.
36. Malenka RC (2003). Synaptic plasticity and AMPA receptor trafficking. Ann NY Acad Sci 1003: 1-11.
37. Malinow R, Malenka RC (2002). AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 25: 103-126.
38. Mammen AL, Kameyama K, Roche KW, Huganir RL (1997). Phosphorylation of the alpha-amino-3-hydroxy-5-methylisoxazole4-propionic acid receptor GluR1 subunit by calcium/ calmodulin-dependent kinase II. J Biol Chem 272: 32528-32533.
39. Manji HK, Lenox RH (2000). Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 48: 518-530.
40. Ossowska K, Pietraszek M, Wardas J, Wolfarth S (2004). Potential antipsychotic and extrapyramidal effects of (R,S)-3,4- dicarboxyphenylglycine [(R,S)-3,4-DCPG], a mixed AMPA antagonist/ mGluR8 agonist. Pol J Pharmacol 56: 295-304.
41. Roche KW, O'Brien RJ, Mammen AL, Bernhardt J, Huganir RL (1996). Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 16: 1179-1188.
42. Rogawski MA, Loscher W (2004). The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 10: 685-692.
43. Rumpel S, LeDoux J, Zador A, Malinow R (2005). Postsynaptic receptor trafficking underlying a form of associative learning. Science 308: 83-88.
44. Shao L, Young LT, Wang JF (2005). Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 58: 879-884.
45. Smith KE, Gibson ES, Dell'Acqua ML (2006). cAMP-dependent protein kinase postsynaptic localization regulated by NMDA receptor activation through translocation of an A-kinase anchoring protein scaffold protein. J Neurosci 26: 2391-2402.
46. Sun X, Zhao Y, Wolf ME (2005). Dopamine receptor stimulation modulates AMPA receptor synaptic insertion in prefrontal cortex neurons. J Neurosci 25: 7341-7351.
47. Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG, Greengard P (2002). Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci USA 99: 3182-3187.
48. Szymczyk G, Zebrowska-Lupina I (2000). Influence of antiepileptics on efficacy of antidepressant drugs in forced swimming test. Pol J Pharmacol 52: 337-344.
49. Vanover KE (1998). Effects of AMPA receptor antagonists on dopamine-mediated behaviors in mice. Psychopharmacology (Berlin) 136: 123-131.
50. Wolf ME, Sun X, Mangiavacchi S, Chao SZ (2004). Psychomotor stimulants and neuronal plasticity. Neuropharmacology 47: 61-79.
51. Zarate Jr CA, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D et al (2004). An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 161: 171-174.
52. Zarate Jr CA, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA et al (2005). An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 57: 430-432.